Gray Elaine, Mulloy Barbara, Barrowcliffe Trevor W
National Institute for Biological Standards & Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK.
Thromb Haemost. 2008 May;99(5):807-18. doi: 10.1160/TH08-01-0032.
Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have replaced the latter in many indications. In this article the chemistry, mechanisms of action, measurement of anticoagulant activities, and clinical status of heparin and LMWH are reviewed.
肝素是最古老的生物药物之一,在静脉血栓形成的预防和治疗中占有一席之地。多家制造商已研发出低分子量肝素(LMWH),其在药代动力学和给药便利性方面具有优势。已证明它们至少与普通肝素一样有效和安全,并且在许多适应症中已取代了普通肝素。本文对肝素和低分子量肝素的化学、作用机制、抗凝活性测定及临床状况进行了综述。